Kiran Mazumdar - Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q3 FY24 Results

Описание к видео Kiran Mazumdar - Shaw, Executive Chairperson, Biocon & Biocon Biologics speaking on Q3 FY24 Results

“A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of ~USD 200 million towards the acquisition related debt reduction.

Steady market shares for key biosimilars in the U.S. and EU were complemented by the Emerging Markets performance which saw a number of new product launches and tender wins.

We continue to make steady progress towards strengthening the foundation for a sustainable growth across all three business segments.” Kiran Mazumdar Shaw comments on Biocon Q3 FY24 results.

Read more for details: bit.ly/PR20240208

Комментарии

Информация по комментариям в разработке

Похожие видео